RE:RE:Maybe....Yes skier a long term moan of mine subsequent to reading the Clinical Protocol given evident potential from preclinical results to become huge as standard of care monotherapy in early stage disease.
Other far less compelling drugs were being trialled ab initio in that setting - why not ours?
Instead TLD-1433 was asked to piss through the eye of a needle in Phase IB.Fortunately (and after much trepidation) it succeeded.
This has not been an easy ride but there is an exceptional future with many unmet needs yet to be addressed by these metal-based photosensitisers. Having come all this way am not selling now.